CD8A and neoplasm: Despite mTOR being essential for antitumor CD8+ memory T cell development Araki et al. (2009); Li et al. (2011), p. 8), systemic treatment with rapamycin impairs CD8+ response Chaoul et al. (2015). Mouse models with persistent mTOR activation showed impaired tumor growth Pollizzi et al. (2015)